- Conditions
- Retinitis Pigmentosa
- Interventions
- Anterior Chamber (AC) tap
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 10,399
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sickle Cell Disease
- Interventions
- nula-cel Drug Product
- Genetic
- Lead sponsor
- Kamau Therapeutics
- Industry
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Palo Alto, California • St Louis, Missouri + 2 more
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blasts Under 25 Percent of Bone Marrow Nucleated Cells, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Burkitt Leukemia, Chronic Monocytic Leukemia, Lymphoblastic Lymphoma, Mast Cell Leukemia, Myeloproliferative Neoplasm
- Interventions
- Total-Body Irradiation, Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Allogeneic Bone Marrow Transplantation, Tacrolimus, Methotrexate, Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation, Echocardiography, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Radiation · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 6 Months to 26 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Atlanta, Georgia • Iowa City, Iowa + 5 more
- Conditions
- Stenosis, Bleed Intracranial, Stroke, TIA, Vascular Malformation, Pseudoaneurysm
- Interventions
- Beacon Tip Catheters
- Device
- Lead sponsor
- Cook Research Incorporated
- Industry
- Eligibility
- Not listed
- Enrollment
- 816 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Darien, Connecticut
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Blastic Phase Chronic Myelogenous Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia
- Interventions
- alvocidib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Atopic Dermatitis
- Interventions
- Tradipitant, Placebo
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Encino, California + 60 more
- Conditions
- Sickle Cell Disease
- Interventions
- Mometasone Furoate, Placebo
- Drug
- Lead sponsor
- Jeffrey Glassberg
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cystic Fibrosis
- Interventions
- Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Cleveland, Ohio
- Conditions
- Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified, Severe Chronic Neutropenia, Chronic Granulomatous Disease (CGD), Hyper IgE Syndromes, Hyper IgM Deficiencies, Wiskott-Aldrich Syndrome, Mendelian Susceptibility to Mycobacterial Disease, Common Variable Immune Deficiency (CVID)
- Interventions
- CD3/CD19 negative allogeneic hematopoietic stem cells
- Biological
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 5 Years to 45 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Sickle Cell Disease
- Interventions
- General Tutoring, Memory Training
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Huntington's Disease (HD)
- Interventions
- Creatine monohydrate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Granulomatous Disease, Chronic
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more
- Conditions
- Nervous System Malformations, Arthropathy, Neurogenic, Urticaria, Papilledema
- Interventions
- anakinra
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Eyelid Dermatochalasis, Dermatochalasis
- Interventions
- Restorative Eye Treatment (RET) cream, INhance with Trihex Technology
- Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Down Syndrome, Child Obesity
- Interventions
- The HomeGrown, Waitlist
- Behavioral · Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Hunter Syndrome
- Interventions
- Idursulfase-IT, Elaprase
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 3 Years to 18 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2024
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Chapel Hill, North Carolina • Portland, Oregon + 4 more
- Conditions
- Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
- Interventions
- Not listed
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- CGB-500 Ointment with 1% tofacitinib, Ruxolitinib 1.5% Cream QD
- Drug
- Lead sponsor
- CAGE Bio Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Fremont, California
- Conditions
- Achondroplasia
- Interventions
- BMN 111
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 6
- States / cities
- Oakland, California • Torrance, California • Chicago, Illinois + 3 more
- Conditions
- Polycystic Liver Disease
- Interventions
- CAM2029, Placebo
- Drug
- Lead sponsor
- Camurus AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 6
- States / cities
- Rochester, Minnesota • New York, New York • Philadelphia, Pennsylvania + 2 more
- Conditions
- Facioscapulohumeral Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Familial Adenomatous Polyposis, Map Syndrome, Lynch Syndrome, Hnpcc, Colorectal Cancer
- Interventions
- Epi proColon Testing
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Thyroid Eye Disease
- Interventions
- AMG 732, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more
- Conditions
- Infant, Premature, Diseases
- Interventions
- Laser Speckle Imaging and Diffuse Optical Spectroscopy
- Device
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 1 Minute to 1 Month
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Orange, California